Graft failure remains a severe complication of hematopoietic stem cell transplantation (HSCT). Several risk factors have already been published. In this study, we re-evaluated them in a large cohort who had the benefit of the recent experience in HSCT (2006HSCT ( -2012. Data from 4684 unrelated donor HSCT from 2006 to 2012 were retrospectively collected from centers belonging to the French Society for Stem Cell Transplantation. Among the 2716 patients for whom HLA typing was available, 103 did not engraft leading to a low rate of no engraftment at 3.8%. In univariate analysis, only type of disease and status of disease at transplant for malignant diseases remained significant risk factors (P = 0.04 and P o 0.0001, respectively). In multivariate analysis, only status of disease was a significant risk factor (P o0.0001). Among the 61 patients who did not engraft and who were mismatched for 1 HLA class I and/or HLA-DP, 5 donor-specific antibodies (DSAs) were detected but only 1 was clearly involved in graft failure, for the others their role was more questionable. Second HSCT exhibited a protective although not statistically significant effect on OS (hazard ratio = 0.57 [0.32-1.02]). In conclusion, only one parameter (disease status before graft) remains risk factor for graft failure in this recent cohort.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is an effective treatment for a broad range of malignant and non-malignant hematologic diseases. Approximately 70% of patients do not have a matched related donor available for transplantation. 1 For these patients, a matched unrelated donor is chosen because of similar outcome. 2, 3 In France, allelic HLA typing is performed according to five HLA loci (HLA-A, HLA-B, HLA-C, HLADRB1 and HLA-DQB1). Graft failure remains a severe complication of HSCT because of the high treatment-related mortality associated with this event. Graft failure occurs more frequently in the context of alternative donor transplantation, with an incidence that varies between 4% in matched unrelated donor transplantations and 20% in cord blood and T cell-depleted haplo-identical stem cell transplantations. [4] [5] [6] Several risk factors associated with graft failure have been previously published. HLA disparity, ABO mismatching in the donor/recipient pairs and use of reduced intensity conditioning (RIC) regimens have been associated with an increased risk of graft failure as well as low nucleated cell dose. [7] [8] [9] [10] [11] However, these studies were performed in different time periods with several types of HSCT and HSCT is a field of constant evolution and change. In this study, we reassessed the risk factors for graft failure in a large cohort of HSCT performed according to recent standards (2006) (2007) (2008) (2009) (2010) (2011) (2012) and also discussed the best strategy for these patients after graft failure. 
MATERIALS AND METHODS Patients

Antibody testing
In total, 61 pre-transplant sera out of the 103 patients who did not engraft were collected to retrospectively determine the presence and the specificity of the anti-HLA antibodies using Luminex-based single antigen flow beads (LABScreen Single Antigen class I and II; One Lambda Inc, Canopa Park, CA, USA). All sera were pre-treated with EDTA to get rid of the potential complement interference phenomenon causing underestimation of strong antibodies. Samples were considered positive for specific HLA antigens based on a background adjusted for mean fluorescence intensity (MFI) greater than 1000.
Statistical analysis
Continuous variables are described using median (interquartile range) (minimum; maximum), and qualitative variables using count and percentage. Characteristics of the entire and selected cohorts were presented, and characteristics of unselected and selected patients (according to availability of HLA data) were compared using exact Fisher's test or Wilcoxon rank-sum test. Among the selected cohort, characteristics of patients with graft failure and engraftment were compared. To identify independent risk factors of graft failure, variables significantly associated with graft failure with a P-value of o0.1 in univariate analysis were entered in a multivariate logistic regression model on the subset of patients with malignant disease. A sensitivity analysis, excluding patients who died during the first 30 days, was performed.
OS was defined as time between from the date of HSCT and death from any cause. The prognostic effect of engraftment on OS was assessed through a Cox proportional hazards model, using engraftment as a timedependent variable. This type of analysis, also known as Mantel-Byar analysis, takes into account the fact that engraftment is not defined at baseline but during the follow-up and thus account for the immortal time bias related to the time between HSCT and definition of engraftment. 12 Finally, the effect of second HSCT was assessed among patients with failure of first HSCT. OS post failure was defined as time between failure of engraftment and death from any cause. A second Cox proportional hazards model with engraftment of the second HSCT as a time-dependent variable was fitted account for the time-dependent nature second HSCT. Statistical analysis were performed with R.2.15.2 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient's characteristics
Patient and transplant characteristics of the entire and selected cohorts are shown in Supplementary Table 1 and Table 1 . In summary, 41, 53 and 7% of patients were transplanted for myeloid malignancies, lymphoid malignancies or non-malignant diseases, respectively. In all, 74% of patients were in CR at the time of HSCT and 57% were transplanted after a myeloablative conditioning (MAC) regimen. The source of the stem cells consisted of BM and PBSCs in 31 and 69% of HSCT, respectively. Median dose of infused total nucleated cell, median CD34 cell dose and median CD3 cell dose are also shown in Supplementary Table 1 and  Table 1 . HLA matching of the selected cohort of 2716 patients was HLA matching 10/10: 58% and mismatched 9/10: 42%. We only observed significant differences between the unselected and selected cohorts regarding 'non-malignant disease' (5% in the unselected cohort vs 7% in the selected cohort) and 'age' (median age 50 vs 46 years in the unselected and selected cohorts, respectively).
Risk factors for non-engraftment Univariate analyses (Table 2) were performed in the selected cohort, and the results are shown in Table 2 . We observed a significant difference in the repartition between myeloid, lymphoid and non-malignant diseases between patients who did not engraft vs patients who did (P = 0.04). We found also 56% Abbreviations: MAC = myeloablative conditioning; NA = not applicable; PSC = peripheral stem cell; RIC = reduced intensity conditioning.
Risk factors and outcome of graft failure after M/MMUD HSCT T Cluzeau et al vs 44% of graft failure in patients without CR vs with CR for malignant diseases, respectively (Po 0.0001). We did not observe an impact of HLA matching, infused total nucleated cell dose (P = 0.52) nor CD34+ cell dose (P = 0.12) even if the source of stem cells is taken into account.
The results of multivariate analysis are shown in Table 3 . The only independent predictor of non-engraftment was the status of malignant disease before transplant with the absence of CR being associated with more failure (OR = 3.18 [2.06-4.91], P o 0.0001). A sensitivity analysis, excluding nine patients who died within the first 30 days, exhibited the same results (data not shown).
Anti-HLA antibodies and engraftment Samples from 61 patients who did not engraft and who were mismatched at one HLA class I (n = 17) and/or at at least one HLA-DP (n = 48) in the HvG direction were tested. Anti-HLA antibodies were detected in 45 patients (13 Outcome for patients who did not engraft In all, 36 (35%) out of the 103 patients who did not engraft had a second HSCT and 89% of these patients had an RIC regimen. These patients were transplanted with bone marrow (17%), peripheral stem cells (57%) and cord blood (26%) as the source of stem cells. Second HSCT exhibited a protective although not statistically significant effect on OS (hazard ratio = 0.57 [0.32-1.02]). Conditioning regimen (RIC vs MAC) and the stem cell source had no significant impact on the survival post second allograft.
DISCUSSION
Several risk factors associated with graft failure have been published. HLA disparity, ABO mismatching in the donor/recipient pairs, use of RIC regimens, infections (CMV, HHV6, Parvovirus) and use of drugs inducing myelosuppression (that is, Ganciclovir) have been associated with an increased risk of graft failure. Others Abbreviations: CI = confidence interval; OR = odds ratio; RIC = reduced intensity conditioning. Bold entries signify the unique positive result.
Risk factors and outcome of graft failure after M/MMUD HSCT T Cluzeau et al factors have been identified like low nucleated cell dose.
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The rate of graft failure after RIC regimens has been reported to range from 5 to 30%, as compared with values ranging from 1 to 5% after myeloablative regimens. 10, 11 However, these studies were performed in different time periods with several types of HSC.
In our retrospective study in a large cohort of UD HSCT in a recent period (2006-2012), we confirmed the low rate of graft failure (3.8%) and that engraftment is a factor associated with better OS. Among the studied factors, only status of the disease before transplantation was shown to impact engraftment of HSCTs performed for malignant diseases during this recent period. Interestingly, we did not observe a difference of engraftment between CSP and BM. Graft failure could be explained by some reasons such as disease persistence. In the case of non-CR status before allo-SCT, strategies post transplantation could be discussed to improve engraftment. Identification of risk factors for failure of engraftment allows for proposing new strategies of transplantation to improve engraftment. Beside the selection of a donor against whom the recipient is not immunized, a more immunosuppressive conditioning regimen might help but is also associated with delayed immune reconstitution. Moreover, it has been shown that anti-thymocyte globulin prevented graft failure and could be interesting in this situation. 16 Several studies have identified a high risk of graft failure in patients with DSA undergoing haplo-identical, cord blood or mismatched HSCT. [17] [18] [19] For these types of HSCT that entail several mismatches, screening for DSA is strongly recommended. 20 Because of the impact of DSA on graft failure in mismatched HSCT, we included HLA antibody analysis in the study in which 42% of donor/recipient pairs were mismatched for one HLA class I antigen and 75% for at least one HLA-DP. In sixty-one patients who did not engraft and who were mismatched for one HLA class I and/or HLA-DP, five DSAs were detected with four anti-HLA-DP and one anti-HLA-A11. The anti-HLA-HLA-A11 DSA observed in one patient was certainly responsible of graft failure due to its very high MFI (MFI = 21 755). For the four other cases, the impact of the anti-HLA-DP DSA is more questionable as it is unclear whether anti-HLA antibodies directed against low-expression loci (DPB1 and DQB1) are associated with graft failure. Some cases of rejection due to anti-HLA-DP allo-immunization were reported in renal transplantation, [21] [22] [23] and Ciurea et al. 24 concluded that anti-HLA-DP DSA could be associated with graft failure in unrelated HSCT. 24 Previous studies also showed that the strength of DSAs measured by MFI correlated with the occurrence of graft failure. 18, 19 An MFI of o500 is commonly considered negative and 47000 strongly positive, but there is no consensus on how to interpret MFI with low or intermediate values. So, in our study, the two anti-DPB1 DSAs with MFI 43000 could be involved in the graft failure but for the two others with weak MFI, this is more questionable. As graft failure is a rare complication, studies with a very large and control cohorts are needed to draw a definitive conclusion on the impact of anti-DP DSA on graft failure and to establish the optimal recipient's cutoff value of MFIs for the donor's selection.
From an older cohort of second allograft not exclusively after non-engraftment, factors indicating higher likelihood for survival were non-malignant disease, a non-relapse indication for the second SCT, full HLA matching and the use of RIC. 25 In our study, the small group of patients who did not engraft and who had a second HSCT had a trend of better OS than patients who did not. Despite the small number of patients, the best strategy could be a reduced intensity conditioning with any stem cell sources. Although we did not observe a significant difference between MAC and RIC with our low number of patients, the use of RIC seems to be more appropriate in this case.
CONCLUSION
Our study showed that with the HSCT management performed since 2005-2006, only status of disease before graft remains a risk factor for graft failure and suggested that the best option after graft failure is a second HSCT after RIC conditioning. Anti-HLA alloimmunization of the patient against the donor is a risk factor for graft failure; however, the impact of DSA with low or intermediate MFI or DSA against anti-DP remains to be established. Risk factors and outcome of graft failure after M/MMUD HSCT T Cluzeau et al
